Shen Lin

Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer

Shen Lin, Shaohong Luo, Lixian Zhong et al. · International Journal of Clinical Pharmacy · 2020 · 67 citations

Oncology, Metronomic Therapy, Bronchial Neoplasm +4

First-Line Treatment With Atezolizumab Plus Nab-Paclitaxel for Advanced Triple-Negative Breast Cancer

Xiuhua Weng, Xiaoting Huang, Hongchao Li et al. · American Journal of Clinical Oncology · 2020 · 42 citations

Cost‐Utility Analysis of Pembrolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer With Different PD-L1 Expression Levels

Xiuhua Weng, Shaohong Luo, Shen Lin et al. · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · 2019 · 32 citations · Full text

Challenges in anticancer drug R&D in China

Shen Zhao, Cheng Lv, Jifang Gong et al. · The Lancet Oncology · 2019 · 23 citations

Medicinal Chemistry, Chemoprevention Strategy, Medicine +7

First-line Treatment with Ribociclib plus Endocrine Therapy for Premenopausal Women with Hormone-receptor-positive Advanced Breast Cancer: A Cost-effectiveness Analysis

Xiaoting Huang, Shen Lin, Xin Rao et al. · Clinical Breast Cancer · 2021 · 18 citations

Breast Oncology, Cost-effectiveness Analysis, Medicine +8